


AMENDMENTS TO THE CLAIMS

1. (Original) A dengue virus infection inhibitor characterized by containing, as the active ingredient, at least a carbohydrate molecule having as an essential constituent an oligosaccharide chain represented by the following formula (I):




(wherein Hex^1 and Hex^2 represent a hexose).

2. (Original) A dengue virus infection inhibitor characterized by containing, as the active ingredient, at least a molecule represented by the following formula (II):



(wherein X represents an oligosaccharide chain represented by the following formula (I):



(wherein Hex^1 and Hex^2 represent a hexose); R is a substrate selected from the group consisting of a hydrogen atom, a substituent having an S, N, O or P atom, a hydrocarbon group, a lipid, a protein and a synthetic polymer, each of which may have a substituent; n is a number of 1 or greater representing the number of the oligosaccharide chains binding to R).

3. (Original) The dengue virus infection inhibitor according to Claim 1 or 2, wherein either a hexose represented by Hex^3 or an aminohexose represented by Hex^3NAc is beta-1-4 linked to the non-reduced end of the oligosaccharide chain represented by the formula (I).

4. (Original) The dengue virus infection inhibitor according to Claim 1 or 2, wherein Hex^1 in the oligosaccharide chain represented by the formula (I) is glucose (Glc), and Hex^2 is galactose (Gal) or mannose (Man).

5. (Original) The dengue virus infection inhibitor according to Claim 3, wherein Hex^1 in the oligosaccharide chain represented by the formula (I) is glucose (Glc), Hex^2 is

galactose (Gal) or mannose (Man), and Hex³ is galactose (Gal) or N-acetyl galactosamine (GalNAc).


6. (Original) The dengue virus infection inhibitor according to Claim 3, wherein the oligosaccharide chain represented by the formula (I) is paragloboside represented by



7. (Original) The dengue virus infection inhibitor according to Claim 3, wherein the oligosaccharide chain represented by the formula (I) is



8. (Original) The dengue virus infection inhibitor according to Claim 3, wherein the oligosaccharide chain represented by the formula (I) is




9. (Cancelled)



10. (Original) A monoclonal antibody to an oligosaccharide chain represented by the following formula (Ib):




11. (Original) A monoclonal antibody to an oligosaccharide chain represented by the following formula (Ic):




12. (Currently Amended) A dengue virus infection inhibitor characterized by containing, as the active ingredient, at least a monoclonal antibody to any one of ~~Claims 9 to 11~~ of the oligosaccharide chains represented by the formulae (Ia) to (Ic):




13. (New) The dengue virus infection inhibitor according to Claim 3, wherein the oligosaccharide chain represented by the formula (I) is




14. (New) A monoclonal antibody to an oligosaccharide chain represented by the following formula (Id):




15. (New) A dengue virus infection inhibitor characterized by containing, as the active ingredient, at least a monoclonal antibody to the oligosaccharide chain represented by the formulae (Id):




16. (New) An oligosaccharide chain represented by the following formula (Ie):



17. (New) The dengue virus infection inhibitor according to Claim 3, wherein the oligosaccharide chain represented by the formula (I) is



18. (New) A monoclonal antibody to an oligosaccharide chain represented by the following formula (Ie):



19. (New) A dengue virus infection inhibitor characterized by containing, as the active ingredient, at least a monoclonal antibody to the oligosaccharide chain represented by the formulae (Ie):

